Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Immunorizon
- Ownership
- Public · PPBT
- Development stage
- Other
01
Overview
Immunorizon developed conditionally activated tri-specific antibodies that engage both T cells and NK cells to mount localized immune responses within the tumor microenvironment. Their lead compound targets the 5T4 antigen and uses cleavable capping technology to confine therapeutic activity to the tumor microenvironment.
- Therapeutic areas
- Oncology
- Modalities
- Tri-specific antibodiesMulti-specific T and NK cell engagers
- Industry
- Biotech
Beyond the preview
Go deeper on Immunorizon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunorizon.